Market Dashboard
- You are here:
- Home
- Markets
- Market Dashboard
- Aurobindo Pharma Ltd.
NSE Symbol: | BSE Code: | ISIN: | Sector:
- Add to Portfolio
- Add to Watchlist
- Add to Alert
- Add to Message
| Change | Change % |
| 35.90 | 5.84% |
Updated:30 May, 2023, 16:01 PM IST |
|
| Change | Change % |
| 36.00 | 5.86% |
Updated:30 May, 2023, 16:01 PM IST |
|
Day's Range
52 Wk Range
Compare Price performance of vs. Peer Companies
From sector
Compare with Peers on Key Fundamentals and Financials
- SUNPHARMA
-1.18% - DIVISLAB
-1.49% - CIPLA
0.93% - DRREDDY
-0.20% - CADILAHC
-0.41% - ABBOTINDIA
0.77% - ALKEM
0.45% - AUROPHARMA
5.86% - LUPIN
3.08% - TORNTPHARM
0.74% - BIOCON
0.94% - GLAXO
0.13% - PFIZER
-0.19% - JBCHEPHARM
2.79% - GLENMARK
0.67% - SANOFI
-0.58% - PEL
0.84% - AJANTPHARM
0.69% - NATCOPHARM
-1.49% - APLLTD
1.64% - IPCALAB
0.53% - MERCK
0.87% - ERIS
0.34% - ASTRAZEN
3.68% - GRANULES
1.79% - CAPLINLABS
0.90% - FDC
3.43% - HIKAL
7.91% - LAURUSLABS
-1.00% - NEULANDLAB
-1.89%
's Latest Research Report
| Brokerage/Analyst | Report Date | Call | Price@Call | Target | Current Status | Report |
|---|---|---|---|---|---|---|
| Nirmal Bang - |
08-07-2019 | Buy | 591.15 | 868.00 | Closed | Details |
| Nirmal Bang - |
11-02-2019 | Buy | 752.60 | 866.00 | Closed | Details |
| Credit Suisse - |
30-05-2017 | Buy | 512.40 | 750.00 | Target Hit | Details |
| Jefferies - |
09-05-2017 | Buy | 594.45 | 1000.00 | Closed | Details |
| Motilal Oswal - |
05-05-2017 | Buy | 592.30 | 900.00 | Closed | Details |
More from Research Reports »
Aurobindo Pharma's Key Fundamentals
| Parameter | Values |
|---|---|
| Market Cap (in ₹ Cr.) | 38,128.49 |
| Earning Per Share (EPS TTM) (₹) | 28.76 |
| Price To Earnings (P/E) Ratio | 22.63 |
| Book Value Per Share (₹) | 170.38 |
| Price To Books (P/B) Ratio | 3.82 |
| EBIT Margin (%) | 23.25 |
| PAT Margin (%) | 17.59 |
| ROCE (%) | 19.02 |
| PAT Growth (%) | 6.21 |
| Total Debt to Equity (D/E) Ratio | 0.37 |
More from Key Fundamentals »
Aurobindo Pharma's Financial Summary
| Parameter | MAR'18 (₹ Cr.) |
MAR'17 (₹ Cr.) |
YoY %Change |
|---|---|---|---|
| Balance Sheet: | |||
| Share Capital | 58.59 | 58.59 | 0.00% |
| Total Non-Current Liabilities | 57.08 | 139.69 | -59.14% |
| Total Current Liabilities | 5,758.34 | 4,446.97 | 29.49% |
| Total Liabilities | 15,798.00 | 13,022.84 | 21.31% |
| Total Non-Current Assets | 6,812.64 | 6,119.49 | 11.33% |
| Currents Investments | 0.02 | 0.02 | 0.00% |
| Cash and Bank | 245.90 | 33.64 | 630.98% |
| Total Current Assets Excluding Current Investments | 8,985.34 | 6,903.33 | 30.16% |
| Total Assets | 15,798.00 | 13,022.84 | 21.31% |
| Profit and Loss: | |||
| Gross Sales | 10,303.15 | 9,781.21 | 5.34% |
| Net Sales | 10,269.90 | 9,607.05 | 6.90% |
| PBIDT (Excl OI) | 2,670.01 | 2,373.95 | 12.47% |
| PAT | 1,812.77 | 1,706.76 | 6.21% |
More from Financial Summary »
Aurobindo Pharma's Shareholding Pattern
| Description | Percent of Share (%) |
|---|---|
| Promoters | 54.76 |
| Individuals | 9.81 |
| Institutions | 16.97 |
| FII | 12.42 |
| Govt. | 0.00 |
| Others | 6.04 |
More from Holding Pattern »
Aurobindo Pharma held by Mutual Fund Schemes
| Scheme | Holding(%) | |
|---|---|---|
| SBI Healthcare Opportunities Fund Regular Plan Dividend | 10.07 |
|
| Reliance Pharma Fund Growth | 8.90 |
|
| Principal Arbitrage Fund Growth | 8.41 |
|
| Quant Consumption Fund Growth | 6.57 |
|
| Quant Focused Fund Growth | 6.28 |
|
| Mirae Asset Healthcare Fund Regular Plan Growth | 6.10 |
|
More from Mutual Fund Holding »
's Futures and Options Quotes
| Contract Expiry Date |
Type | Current price | Change | Change % | Premium / Discount |
|---|---|---|---|---|---|
| AUROPHARMA 29-06-2023 |
FUTSTK |
654.15 | 38.80 | 6.31% | 3.40 |
| AUROPHARMA 27-07-2023 |
FUTSTK |
657.00 | 39.40 | 6.38% | 6.25 |
| AUROPHARMA 31-08-2023 |
FUTSTK |
659.95 | 39.85 | 6.43% | 9.20 |
More from Futures and Options Quotes »
Aurobindo Pharma is a drug maker headquartered in Hyderabad. It is a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients with its product portfolio spread over seven major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and antidiabetics. Aurobindo Pharma markets these products in over 150 countries around the globe. Around 60 per cent of Aurobindo Pharma's sales volume is contributed through exports. In FY17, Aurobindo Pharma registered a net profit of Rs 1,707 crore over revenue of Rs 9,781 crore. As of September 2017, Aurobindo Pharma's promoter group held a 51.87 per cent stake in the company while the remaining 48.13 per cent was with the public.
Aurobindo Pharma shares
Aurobindo Pharma shares trade with symbol AUROPHARMA on stock exchanges BSE and NSE.
History
Aurobindo Pharma was founded in 1986 by P V Ramaprasad Reddy, K Nityananda Reddy and a small group of highly committed professionals. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.
Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995.
BackgroundAurobindo Pharma is one of the world's top five manufacturers of semi synthetic penicillin, as well as one of India's top five pharma companies ranked in terms of turnover.
Registered office
Aurobindo Pharma Limited, Plot no. 2, Maitrivihar, Ameerpet, Hyderabad-500038